Clinical Report: Reevaluating Immunotherapy in Colorectal Cancer Liver Metastases

Background

Colorectal cancer liver metastases (CRLM) significantly contribute to systemic immunosuppression and are associated with poor clinical outcomes. While immunotherapy has shown promise in certain molecularly defined populations, the presence of liver metastases complicates treatment efficacy and patient prognosis. Understanding the interactions between liver disease and immunotherapy is crucial for optimizing treatment strategies.

Data Highlights

Key Findings

• dMMR/MSI-H status is the primary biomarker for immunotherapy in metastatic colorectal cancer.
• Liver metastases are associated with poorer outcomes in both dMMR/MSI-H and pMMR/MSS cohorts.
• Active liver disease may limit the efficacy of immunotherapy but is not a contraindication for treatment.
• Clinical benefit from immunotherapy is significantly lower in patients with active liver metastases.
• Prior complete metastasectomy is associated with improved outcomes in patients with liver metastases.

Clinical Implications

Clinicians should consider liver disease status when evaluating treatment options for colorectal cancer patients. Active liver disease may limit the efficacy of immunotherapy but is not a contraindication for treatment.

Conclusion

The hepatic metastatic microenvironment plays a critical role in the efficacy of immunotherapy for colorectal cancer, necessitating further research to optimize treatment strategies in this patient population.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Systemic immune remodeling following curative (R0) resection of colorectal liver metastases
2. Frontiers in Immunology, 2026 -- Organ-specific pre-metastatic and metastatic niches in colorectal cancer: “discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis”
3. Frontiers in Immunology, 2026 -- Colorectal cancer liver metastases: mechanism and therapy
4. Frontiers in Immunology, 2026 -- NAFLD-associated immune remodeling in colorectal cancer liver metastasis: mechanisms and implications for immunotherapy
5. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
6. Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer - PMC
7. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
8. Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer - PMC